T2 BIOSYSTEMS INC (TTOO) Fundamental Analysis & Valuation
NASDAQ:TTOO • US89853L3024
Current stock price
0.134 USD
-0.06 (-31.07%)
At close:
0.12 USD
-0.01 (-10.45%)
After Hours:
This TTOO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TTOO Profitability Analysis
1.1 Basic Checks
- In the past year TTOO has reported negative net income.
- TTOO had a negative operating cash flow in the past year.
- TTOO had negative earnings in each of the past 5 years.
- TTOO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- TTOO has a Return On Assets of -237.55%. This is amonst the worse of the industry: TTOO underperforms 92.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -237.55% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TTOO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. TTOO Health Analysis
2.1 Basic Checks
- TTOO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, TTOO has more shares outstanding
- The debt/assets ratio for TTOO has been reduced compared to a year ago.
2.2 Solvency
- TTOO has an Altman-Z score of -55.84. This is a bad value and indicates that TTOO is not financially healthy and even has some risk of bankruptcy.
- TTOO has a worse Altman-Z score (-55.84) than 95.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -55.84 |
ROIC/WACCN/A
WACC7.42%
2.3 Liquidity
- A Current Ratio of 0.40 indicates that TTOO may have some problems paying its short term obligations.
- TTOO has a worse Current ratio (0.40) than 94.49% of its industry peers.
- A Quick Ratio of 0.24 indicates that TTOO may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.24, TTOO is doing worse than 96.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.24 |
3. TTOO Growth Analysis
3.1 Past
- TTOO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.25%, which is quite impressive.
- The Revenue for TTOO has decreased by -30.16% in the past year. This is quite bad
- The Revenue has been decreasing by -7.29% on average over the past years.
EPS 1Y (TTM)97.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.59%
Revenue 1Y (TTM)-30.16%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%34.85%
3.2 Future
- Based on estimates for the next years, TTOO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.64% on average per year.
- Based on estimates for the next years, TTOO will show a very strong growth in Revenue. The Revenue will grow by 54.19% on average per year.
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. TTOO Valuation Analysis
4.1 Price/Earnings Ratio
- TTOO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TTOO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TTOO's earnings are expected to grow with 25.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.13%
EPS Next 3Y25.19%
5. TTOO Dividend Analysis
5.1 Amount
- TTOO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TTOO Fundamentals: All Metrics, Ratios and Statistics
0.134
-0.06 (-31.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-05 2025-05-05
Inst Owners3.18%
Inst Owner Change0%
Ins Owners0.1%
Ins Owner Change0%
Market Cap3.76M
Revenue(TTM)7.68M
Net Income(TTM)-42.95M
Analysts43.33
Price Target5.1 (3705.97%)
Short Float %0.03%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.68%
Min Revenue beat(2)-30.5%
Max Revenue beat(2)-8.87%
Revenue beat(4)1
Avg Revenue beat(4)-7.69%
Min Revenue beat(4)-30.5%
Max Revenue beat(4)26.29%
Revenue beat(8)1
Avg Revenue beat(8)-6.63%
Revenue beat(12)3
Avg Revenue beat(12)-6.67%
Revenue beat(16)6
Avg Revenue beat(16)-2.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.82
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.27
BVpS-0.42
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -237.55% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | -55.84 |
F-Score3
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)30.32%
Cap/Depr(5y)34.46%
Cap/Sales(3y)1.94%
Cap/Sales(5y)3.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.59%
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue 1Y (TTM)-30.16%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%34.85%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%
EBIT growth 1Y12.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.02%
OCF growth 3YN/A
OCF growth 5YN/A
T2 BIOSYSTEMS INC / TTOO Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for T2 BIOSYSTEMS INC?
ChartMill assigns a fundamental rating of 1 / 10 to TTOO.
Can you provide the valuation status for T2 BIOSYSTEMS INC?
ChartMill assigns a valuation rating of 1 / 10 to T2 BIOSYSTEMS INC (TTOO). This can be considered as Overvalued.
Can you provide the profitability details for T2 BIOSYSTEMS INC?
T2 BIOSYSTEMS INC (TTOO) has a profitability rating of 0 / 10.
Can you provide the financial health for TTOO stock?
The financial health rating of T2 BIOSYSTEMS INC (TTOO) is 0 / 10.
What is the earnings growth outlook for T2 BIOSYSTEMS INC?
The Earnings per Share (EPS) of T2 BIOSYSTEMS INC (TTOO) is expected to grow by 83.26% in the next year.